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Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor 
which arises from thyroid C-cells. It accounts for 5 to 10% of all thyroid cancers. 
Total thyroidectomy with lymph node dissection is the main treatment when the 
disease is confined to the neck Dacarbazine (DTIC), also known as imidazole 
carboxamide, is a chemotherapy medication used in the treatment of melanoma and 
Hodgkin's lymphoma. For Hodgkin's it is often used with vinblastine, bleomycin, 
and doxorubicin. It is given by injection into a vein. Common side effects include 
loss of appetite, vomiting, low white blood cell count, and low platelets. Other 
serious side effects include liver problems and allergic reactions. Dacarbazine is in 
the alkylating agent and purine analog families of medication 
 
 Methods and Results: Their mean age was 49 years (range 30–79). There were 
25males and 11females. Among them, 19 had undergone a total thyroidectomy with 
bilateral cervical lymph node dissection, and 10 had received post-operatively 
external radiotherapy to the neck and mediastinum. seven patients were not operated 
on for diffuse distant metastases at presentation or locally advanced disease. None of 
them had previously been treated with chemotherapy. 
Results: The 37patients entered into this trial were evaluable for toxicity and 
response. Each patient received an average of 6 (range 7 to 5) cycles of doxorubicin-
streptococci and 5-FU-dacarbazine. five of the 7 patients with invalidating 
symptoms before starting chemotherapy had a partial symptomatic response. Three 
partial tumor responses were obtained after 1, 3 and 2 cycles of chemotherapy, and 
lasted 11, 19+ and 10 months, respectively. Calcitonin level decreased by 72%, 86% 
and 68% respectively, and CEA level was stable in one patient, was normal in one 
before therapy, and decreased by 55% in one. 
Conclusion: Considering that all patients included in the trial were affected by a 
rapidly progressing disease, these results confirm the potential benefits of cytotoxic 
chemotherapy, and are in agreement with the results obtained with the association of 
epirubicin, dacarbazine and 5-FU 
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